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Abstract
Background: Patients with a hemispheric infarct and massive space-occupying brain oedema have
a poor prognosis. Despite maximal conservative treatment, the case fatality rate may be as high as
80%, and most survivors are left severely disabled. Non-randomised studies suggest that
decompressive surgery reduces mortality substantially and improves functional outcome of
survivors. This study is designed to compare the efficacy of decompressive surgery to improve
functional outcome with that of conservative treatment in patients with space-occupying
supratentorial infarction
Methods: The study design is that of a multi-centre, randomised clinical trial, which will include
112 patients aged between 18 and 60 years with a large hemispheric infarct with space-occupying
oedema that leads to a decrease in consciousness. Patients will be randomised to receive either
decompressive surgery in combination with medical treatment or best medical treatment alone.
Randomisation will be stratified for the intended mode of conservative treatment (intensive care
or stroke unit care). The primary outcome measure will be functional outcome, as determined by
the score on the modified Rankin Scale, at one year.
Background
Large cerebral infarcts are commonly associated with var-
iable degrees of brain oedema. In severe cases, this may
lead to transtentorial or uncal herniation. Serious oedema
formation usually manifests itself between the second and
fifth day after stroke onset [1-4]. Brain tissue shifts rather
than raised intracranial pressure (ICP) are probably the
most likely cause of the initial decrease in consciousness
[4,5].
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1 to 5% of patients with a supratentorial infarct [6,7].
However, in younger patients with ischaemic stroke, her-
niation accounts for about half of the deaths in the first
month [8]. Patients with a hemispheric infarct and mas-
sive space-occupying brain oedema have a poor progno-
sis: in recent intensive care (IC)-based prospective series,
the case fatality rate was about 80%, despite maximal con-
servative therapy [9,10].
Several conservative treatment strategies have been pro-
posed to limit brain tissue shifts and reduce intracranial
pressure, such as sedation with barbiturates or propofol,
hyperventilation, and osmotic therapy with glycerol,
mannitol, or hypertonic saline hydroxyethyl starch (HES)
[11-13]. However, no trials have addressed the efficacy of
these therapies to improve clinical outcome [14], and sev-
eral reports suggest that these are ineffective [9,10,15] or
even detrimental [16,17]. The value of ICP monitoring
has also not been established. ICP monitoring may reduce
iatrogenic errors [18], but is probably not helpful in guid-
ing long-term treatment [5]. Despite this lack of evidence
hyperventilation, osmotherapy, and the use of ICP moni-
tors are recommended and used by experts for patients
with ischaemic stroke whose condition is deteriorating
secondary to oedema formation [11,12,19].
Because of the limitations of medical therapies, there have
been proposals for decompressive surgery in patients with
neurological deterioration due to large hemispheric inf-
arction and oedema. The rationale of this therapy is to
prevent brain tissue shifts and to normalise intracranial
pressure, and thereby to preserve cerebral blood flow and
to prevent secondary damage [19]. The technique of
decompressive surgery is relatively simple and consists of
a large hemicraniectomy and a duraplasty. It can be per-
formed in every neurosurgical centre.
Animal studies have shown that decompressive surgery
reduces mortality and improves histological and func-
tional outcome [20,21]. Case reports and small retrospec-
tive studies have suggested that this intervention lowers
mortality without increasing the rate of severely disabled
survivors [19,22,23]. These findings were supported by
two prospective series. Mortality was reduced from about
80% in controls to 34% and 16% in surgically treated
patients, respectively, and poor functional outcome from
95% to 50% [24,25]. Reports from other studies suggest
that decompressive surgery is less effective in elderly
patients [26,27], and that substantial recovery extends
into the second half year and thereafter [28].
Although the above results suggest a very substantial ben-
efit of decompressive surgery, the studies had too many
flaws to be readily translated into clinical practice. Most
importantly, the groups were not constituted by random
selection. The control groups consisted of patients with a
significantly higher age, more co-morbidity, and more fre-
quent lesions in the dominant hemisphere than those in
the surgical groups [24,25]. In addition, information on
functional outcome of the surviving patients was insuffi-
cient [24,25].
The aim of the current study is to test if decompressive sur-
gery would improve functional outcome in patients with
neurological deterioration due to large hemispheric inf-
arction and oedema, as compared with 'standard' best
medical care, on either a stroke unit (SU) or an ICU, in a
randomised controlled clinical trial.
Methods and design
This is a multi-centre, open, randomised treatment trial
with masked outcome assessment. Participating centres
have adequate experience with the management of acute
ischaemic stroke and intensive care treatment of patients
with an elevated ICP, and neurosurgical facilities are avail-
able on a 24-hours/day basis. The trial protocol has been
approved by the medical ethical committees of all partic-
ipating centers.
Enrollment criteria
Patients can be enrolled in the study if they have 1. a diag-
nosis of acute ischaemic stroke in the territory of the mid-
dle cerebral artery, with an onset within 96 hours prior to
the planned start of the trial treatment. Within this time-
frame, it is advised to start treatment as soon as possible;
2. a score on the National Institutes of Health Stroke Scale
(NIHSS) [29] ≥ 16 for right-sided lesions or ≥ 21 for left-
sided lesions; 3. a gradual decrease in consciousness to a
score of 13 or lower on the Glasgow Coma Scale (GCS) for
right-sided lesions, or an eye and motor score of 9 or
lower for left-sided lesions; 4. hypodensity on CT involv-
ing two thirds or more of the territory of the middle cere-
bral artery (MCA), and space-occupying oedema
formation. (displacement of midline structures on CT is
not a requirement for inclusion); and 5. age 18 up to and
including 60 years. In addition, there must be a possibility
to start trial treatment within 3 hours after randomisation,
and written informed consent must be obtained from a
representative of the patient.
Patients will be excluded from the study if they have 1.
ischaemic stroke of the entire cerebral hemisphere (ante-
rior, middle, and posterior cerebral artery territories); 2. a
decrease in consciousness at least partially explained by a
cause other than oedema formation, such as metabolic
disturbances or medication; 3. two fixed dilated pupils; 4.
been treated with a thrombolytic agent in the 12 hours
preceding randomisation; 5. a known systemic bleeding
disorder; 6. a pre-stroke score on the modified RankinPage 2 of 7
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(BI) of less than 95 [31], 7. a life expectancy < 3 years, or
8. a serious illness that may confound treatment assess-
ment.
Informed consent
Written informed consent for this study will be obtained
from the patient's authorised representative prior to the
performance of any protocol-specific procedure. How-
ever, several of these assessments or tests may be per-
formed as part of the patient's routine clinical evaluation
(i.e. not specifically performed for this trial). The study
will be conducted in accordance with the provisions of the
Declaration of Helsinki, as amended in South Africa
(1996).
Treatment allocation
After informed consent is obtained, patients will be ran-
domised to either surgical or conservative treatment. Ran-
domisation will be stratified for the intended mode of
conservative treatment (intensive care or stroke unit care;
see below). The choice of conservative treatment is left at
the discretion of the local investigator, and will usually be
the standard mode of treatment in the participating cen-
tre. Allocation to treatment will be made via a telephone
call to a 24 hour randomisation service. Ideally, each treat-
ment arm will consist of 56 patients. The total number of
patients included in the trial will be 112.
I. decompressive surgery
Decompressive surgery will consist of a large hemicraniec-
tomy and a duraplasty. In summary, a large (reversed)
question mark-shaped skin incision based at the ear will
be made. A bone flap with a diameter of at least 12 cm
(including parts of the frontal, parietal, temporal, and
occipital squama) will be removed. Additional temporal
bone will be removed so that the floor of the middle cer-
ebral fossa can be explored. The dura will be opened and
an augmented dural patch will be inserted. The dura will
be fixed at the margins of the craniotomy to prevent epi-
dural bleeding. The temporal muscle and the skin flap will
then be re-approximated and secured. Infarcted brain tis-
sue will not be resected. A sensor for registration of intrac-
ranial pressure may be inserted. In surviving patients,
cranioplasty will be performed after at least six weeks,
using the stored bone flap or acrylate. After surgery,
patients will be transferred to an IC unit. Anti-oedema
therapy as described under 'IIa' may be used but will usu-
ally not be necessary.
IIa. intensive care
Because no mode of IC treatment has been proven supe-
rior to the others, treatment options may vary depending
on local traditions. However, to improve consistency of
treatment between centres, the following treatment
modalities are recommended:
a. Osmotherapy. Osmotherapy should be started as soon as
possible after randomisation. The use of mannitol or glyc-
erol is recommended in a dose sufficient to reach a serum
osmolality of 315 to 320 mOsm.
b. Intubation and mechanical ventilation. Patients will be
intubated if the score on the GCS is lower than or equal to
10, or if there are signs of respiratory insufficiency, such as
a pO2 ≤ 60 mm Hg, a pCO2 ≥ 60 mm Hg, or if the airway
is compromised. However, earlier intubation is left at dis-
cretion of the treating physician. Mechanical ventilation
with use of intermittent mandatory or assist/control ven-
tilation will often be sufficient, especially in the early
phase.
c. Hyperventilation. The use of hyperventilation is discour-
aged. If hyperventilation is started, it is advised to monitor
venous oxygen saturation with jugular bulb oxymetry and
to maintain oxygen saturation higher than 50%. If venous
oxygen saturation is not monitored, the pCO2 may be
reduced to 28 – 32 mm Hg.
d. ICP monitoring. Invasive monitoring of the intracranial
pressure is left at the discretion of the treating physician.
If used, the ICP monitor should preferably be inserted
ipsilateral to the side of the infarct.
e. Sedation. If mechanical ventilation requires sedation,
and in the case of further neurological deterioration, or an
uncontrolled increase in ICP, patients may be sedated
with propofol. The use of barbiturates is discouraged,
because this may reduce cerebral perfusion pressure and
does often not lead to a sustained control of ICP. If neces-
sary, muscle relaxants may be used.
f. Blood pressure control. In general, spontaneous elevation
of blood pressure to a level of 220/120 mm Hg should be
accepted. Sustained higher blood pressures can be treated
with labetolol or nitroprusside. In case of sustained hypo-
tension or a critical reduction of cerebral perfusion pres-
sure catecholamines may be used.
g. Elevation of the head (30°) to optimise venous drainage.
h. Aim for normothermia. Antipyretics and a cooling blan-
ket may be used.
i. Aim for normoglycaemia. Consider the use of insulin.
IC treatment should be continued at least until day 5 after
stroke onset, or until there is clinical or radiologicalPage 3 of 7
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patient back to the stroke unit or medium care unit.
IIb. stroke unit care
The patient will be admitted to a stroke unit or medium
care unit and is treated according to local practice, supple-
mented with the treatment options that can be performed
in a medium care unit as described above under 'a'.
Treatment strategy 'I' is the experimental option, strategy
'IIa' is recommended by international experts, and strat-
egy 'IIb' is the most common clinical practice in the Neth-
erlands, and probably also in a significant number of
other European countries.
The choice of ancillary care measures, e.g., prophylactic
administration of (low-molecular-weight) heparin and
the treatment of complicating illnesses, will be at the dis-
cretion of the treating physician. However, administration
of low-dose aspirin is recommended, whereas treatment
with intravenous heparin and haemodilution with
plasma expanders are discouraged.
Outcome assessment
The primary outcome measure will be functional out-
come, as determined by the score on the mRS, at one year.
Outcome will be dichotomised as 'good' (mRS 0 to 3) or
poor (mRS 4 to dead). The score on the mRS will be deter-
mined in a standard way independently by three blinded
investigators, on the basis of a narrative written by an
unblinded independent study nurse, if necessary followed
by a consensus meeting. Secondary analyses will be per-
formed in which 'good outcome' will be defined as mRS 0
to 2, and 'poor outcome' as mRS 3 to dead, and with case
fatality as the measure of outcome. Other outcome meas-
ures will include the scores on the NIHSS, the BI, and the
Montgomery and Asberg Depression Rating Scale
(MADRS) [32] and quality of life as measured with the
SF3633 and with a visual analogue scale (VAS) [33] at one
year and at three years. In addition, the mRS, NIHSS, and
BI will be determined at 3 and 6 months.
Data collection
At baseline, the medical history will be assessed and a gen-
eral and neurological examination will be carried out. The
scores on the GCS and NIHSS will be used to assess stroke
severity on admission and directly prior to randomisa-
tion. Retrospective scoring of the NIHSS on admission is
reliable when a published algorithm is used [34]. Date
and time of stroke onset and of neurological deterioration
(i.e. GCS ≤ 13) will be noted. Laboratory investigations
will include a blood cell count, electrolytes, serum glu-
cose, creatinine, and liver enzymes. Brain CT or MRI scans
will be performed on admission and prior to randomisa-
tion. Lateral displacement of the pineal gland and the sep-
tum pellucidum will be measured by the trial co-
ordinator.
The GCS, pupillary reflexes, body temperature, and blood
pressure will be assessed every 4 hours during the first 4
days after randomisation. If ICP is recorded, ICP and cer-
ebral perfusion pressure (CPP) will be noted at 2-hour
intervals. Dose and time of administration of osmotic
agents and sedatives, concurrent medication, and neuro-
logical and systemic adverse events will be recorded. The
GCS, NIHSS, mRS, and BI will be determined at day 14.
CT or MRI of the brain will be performed at day 7 ± 2 days
for measurement of infarct volume [35,36] and lateral dis-
placement of the pineal gland and septum pellucidum.
At three and six months, the mRS, BI, and NIHSS will be
assessed. Serious adverse events and the number of days
the patient was admitted on an IC unit, in the hospital,
and/or rehabilitation centre or chronic nursing home will
be recorded.
At one and three years, the mRS, BI, MADRS, VAS, and
SF36 will be assessed by the research fellow or data man-
ager. He/she will perform a standardised evaluation of
each patient, including functional status, and will include
the obtained information in an essay. Based on this essay,
three members of the executive committee, who are
blinded to treatment allocation, will determine the scores
on the mRS and BI.
Statistical aspects
In the primary analysis, outcome of all patients in the sur-
gical group will be compared with that of all patients in
the conservative treatment group. However, subgroup
analyses will be performed based on the mode of conserv-
ative treatment (intensive care vs. stroke unit care), side of
the lesion, and time of randomisation (within 48 hours
versus between 48 and 96 hours). The sample size is based
on the desire that in each of the two subgroups the supe-
riority of surgical decompression over conservative treat-
ment can be proved. All primary analyses will be
performed on an intention-to-treat basis, but additional
on-treatment analyses will also be performed. An interim
analysis will be performed after the one-year follow-up of
the first 30 patients.
Power calculations are hampered by the scarcity of data
on clinical outcome in this patient group. In the non-ran-
domised trial by Rieke et al., which is most comparable to
the proposed study regarding patient group and treat-
ment, 95% (20/21) of the patients in the IC treatment
group had a poor outcome, compared with 50% (16/32)
in the surgically treated group [24]. There are no data on
outcome after 'standard' treatment, but this is not likely to
be better than IC treatment. Based on an α of 0.05 and aPage 4 of 7
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patients would have to be included in each group to dem-
onstrate the superiority of surgical decompression over
conservative treatment in a randomised trial. Assuming
that 60% of the patients in the surgery group will have a
poor outcome and 85% of the patients in each of the two
conservative treatment subgroups, a group size of 28
patients would suffice to prove the superiority of decom-
pressive surgery (table 1). Results of applying the same
assumption to the complete treatment groups are shown
in table 2.
Safety
In the conservative treatment group, patients will receive
the standard care of the centre to which they have been
admitted. For this reason, the components of the conserv-
ative treatment strategies will not be considered experi-
mental, and need no detailed explanation in patient
information letters.
Decompressive surgery consisting of a hemicraniectomy
and a duraplasty may be complicated by the occurrence of
local postoperative bleeding. In the two open, prospective
studies of decompressive surgery for space-occupying
hemispheric infarction, including a total of 63 patients, 3
patients (5%; 95% CI, 0 to 13) experienced an epidural
haematoma, one (2%; 95% CI, 0 to 9) a subdural hae-
matoma, and three (5%; 95% CI, 0 to 13) a space-occupy-
ing subarachnoid hygroma over the trepanation site.
None of these complications led to an additional neuro-
logical deficit [9,25].
An adverse event is any unfavourable and unintended
sign, symptom, or disease occurring during the follow-up
period of the study. Adverse events occurring after ran-
domisation will be recorded on the adverse event page of
the CRF. A serious adverse event is defined as any adverse
event that results in death, a life-threatening condition,
inpatient hospitalisation or prolongation of existing hos-
pitalisation, or persistent or significant disability/incapac-
ity. An important medical event that may not result in one
of the above conditions may be considered a serious
adverse event when, based upon medical judgement, it
may jeopardise the patient and may require medical or
surgical intervention to prevent one of the outcomes
above.
A reasonably-related adverse event is defined as one that
is possibly, probably, or definitely related to the trial treat-
ment. Adverse events that are serious and reasonably
related to the trial treatment, and all deaths, require com-
pletion of the safety report, which should be faxed to the
trial co-ordination centre within 5 working days of obser-
vation or notification of the event.
The Data Monitoring Committee performs analyses of the
unblinded interim data and formulates recommendations
for the Steering Committee on the continuation of the
trial. The Data Monitoring Committee may also offer
unsolicited recommendations.
Publication of the trial results
The trial results will be published by the members of the
Executive Committee, on behalf of all HAMLET investiga-
tors. Before submission of any manuscript all local princi-
pal investigators will have the opportunity to comment
on the manuscript.
Discussion
We present the protocol of a randomised clinical trial
designed to test the efficacy of decompressive surgery to
improve functional outcome in patients with space-occu-
pying hemispheric infarction. Case reports, retrospective
studies and two trials have suggested that this intervention
lowers mortality without increasing the rate of severely
disabled survivors [19,22-25], but this has never been
tested in a randomised, controlled clinical trial.
The timing of surgery and the choice of enrolment criteria
form the crux of the present trial. It has been suggested
that decompressive surgery is most efficacious if per-
formed within the first 24 hours after stroke onset and
before the occurrence of clinical signs of herniation [25],
but this may carry the risk of inclusion of patients who do
not need such an invasive procedure for survival and
recovery. In addition, in a systematic review of studies on
decompressive surgery in space-occupying hemispheric
Table 1: Results expected for each of the two treatment arms 
assuming 60% poor outcome after surgery and 85% poor 
outcome after conservative treatment
surgery n = 28 conservative treatment n = 28
Poor outcome (n) 17 24
RR (95% CI) 0.71 (0.51–0.99) ref
RR denotes relative risk; CI, confidence interval. Conservative 
treatment indicates IC or SU treatment.
Table 2: Results expected for the complete treatment groups 
assuming 60% poor outcome after surgery and 85% poor 
outcome after conservative treatment
surgery n = 56 conservative treatment n = 56
Poor outcome (n) 34 48
RR (95% CI) 0.71 (0.56–0.90) ref
RR denotes relative risk; CI, confidence interval.Page 5 of 7
(page number not for citation purposes)
Trials 2006, 7:29 http://www.trialsjournal.com/content/7/1/29infarction, the timing of surgery did not affect outcome
[27].
In different studies, several clinical and radiological
parameters have been identified as independent early pre-
dictors of fatal space-occupying oedema formation: nau-
sea and vomiting within 24 hours after stroke onset [37],
a systolic blood pressure of 180 mm Hg or more at 12
hours after onset [37], a history of hypertension or heart
failure [38], elevated white blood cell count [38], an activ-
ity deficit covering the complete MCA territory on SPECT
imaging [39], a hypodensity of more than 50% on the ini-
tial CT scan [38,37], attenuated corticomedullary contrast
on CT [40], involvement of additional vascular territories
[38], and volume of diffusion-weighted imaging (DWI)
abnormalities of more than 145 ml [41]. In addition, in
the Lubeluzole-International-9 trial it was found that the
minimum baseline score in patients who ultimately died
from brain swelling was 15 for right-sided lesions and 20
for left-sided lesions [37]. Unfortunately, all studies were
relatively small and the value of the suggested predictors
has not been confirmed in other prospective series. With
the proposed timing of therapy and choice of enrolment
criteria we expect to largely prevent inclusion of patients
who cannot benefit from hemicraniectomy, either
because they do not need decompressive surgery since
their disease will follow a more benign course, or because
of extensive and irreversible damage.
In the Heidelberg studies, complete global aphasia was an
exclusion criterion for decompressive surgery, and the
majority of patients receiving surgical therapy had a lesion
in the right hemisphere [24,25]. In our study, patients
with a large infarct in the dominant hemisphere and
severe aphasia may be included, as it is unproven that they
will fare worse than patients with an infarct in the non-
dominant hemisphere. In fact, it has been shown that
with the exception of the ability to communicate, the
long-term quality of life of patients with left-sided lesions
is slightly better than that of patients with a lesion in the
right hemisphere [42].
In this trial, a fully blinded evaluation of the functional
outcome of patients is virtually impossible, as patients in
the decompressive surgery group will be easily recognised
by surgical marks. Even in case of follow up by telephone,
patients are likely to note the sequels of surgery. However,
sufficient blinding will be assured by the indirect assess-
ment of scores on the functional outcome scales, as
described above.
The trial started 1 September 2002. As of 1 July 2006, 52
patients were included in seven participating centres in
the Netherlands. Two other Dutch centres and seven cen-
tres in the UK are expected to join the trial shortly. Other
centres that have adequate experience with the manage-
ment of acute ischaemic stroke and intensive care treat-
ment of patients with an elevated ICP, and that have
neurosurgical facilities available on a 24-hours/day basis
are welcome to participate.
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